Occupational exposure to antineoplastic agents induces a high level of chromosome damage. Lack of an effect of GST polymorphisms

Toxicology and Applied Pharmacology

Volumn 223, Issue 1, 2007, Pages 46-55

  Testa, Antonella ^a   Giachelia, Manuela ^a   Palma, Selena ^a   Appolloni, Massimo ^a   Padua, Luca ^c   Tranfo, Giovanna ^d   Spagnoli, Mariangela ^d   Tirindelli, Donatella ^a   Cozzi, Renata ^b  

^a ENEA   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d Occupational Hygiene Department   (Italy)

Author keywords

Antineoplastic drugs; Chromosome aberrations; GSTs polymorphisms; Occupational exposure

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AZATHIOPRINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUOROURACIL; GENOMIC DNA; GLUTATHIONE TRANSFERASE; HORMONE; METHOTREXATE; PACLITAXEL; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CHROMATID ABERRATION; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL PERSONNEL; HUMAN; HUMAN CELL; ITALY; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; NURSE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; ONCOLOGY NURSING; QUESTIONNAIRE;

ADULT; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MUTAGENS; OCCUPATIONAL EXPOSURE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSLOCATION, GENETIC;

EID: 34547784016     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.05.006     Document Type: Article

References (58)

1. Ambrosone C.B., Sweeney C., Coles B.F., Thompson P.A., McClure G.Y., Korourian S., Fares M.Y., Stone A., Kadlubar F.F., and Hutchins L.F. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61 (2001) 7130-7135
2. Anderer G., Schrappe M., Brechlin A.M., Lauten M., Muti P., Welte K., and Stanulla M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 10 (2000) 715-726
3. Anwar W.A., Salama S.I., el Serafy M.M., Hemida S.A., and Hafez A.S. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis 9 (1994) 315-317
4. Barale R., Sozzi G., Toniolo P., Borghi O., Reali D., Loprieno N., and Della Porta G. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat. Res. 157 (1985) 235-240
5. Bonassi S., and Au W.W. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat. Res. 511 (2002) 73-86
6. Bonassi S., Abbondandolo A., Camurri L., Dal Pra L., De Ferrari M., Degrassi F., Forni A., Lamberti L., Lando C., and Padovani P. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet. Cytogenet. 79 (1995) 133-135
7. Bonassi S., Hagmar L., Stromberg U., Montagud A.H., Tinnerberg H., Forni A., Heikkila P., Wanders S., Wilhardt P., Hansteen I.L., Knudsen L.E., and Norppa H. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res. 60 (2000) 1619-1625
8. Bonassi S., Ugolini D., Kirsch-Volders M., Stromberg U., Vermeulen R., and Tucker J.D. Human population studies with cytogenetic biomarkers: review of the literature and future prospectives. Environ. Mol. Mutagen. 45 (2005) 258-270
9. Burgaz S., Karahalil B., Canhi Z., Terzioglu F., Ancel G., Anzion R.B., Bos R.P., and Huttner E. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Human Exp. Toxicol. 21 (2002) 129-135
10. Carrano A.V., and Natarajan A.T. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. Mutat. Res. 204 (1988) 379-406
11. Cavallo D., Ursini C.L., Perniconi B., Francesco A.D., Giglio M., Rubino FM., Marinaccio A., and Iavicoli S. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat. Res. 587 (2005) 45-51
12. Chen J., and Stubbe J. Bleomycins: towards better therapeutics. Nat. Rev., Cancer 5 (2005) 102-112
13. Coles B.F., Morel F., Rauch C., Huber W.W., Yang M., Teitel C.H., Green B., Lang N.P., and Kadlubar F.F. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11 (2001) 663-669
14. Davies S.M., Robison L.L., Buckley J.D., Tjoa T., Woods W.G., Radloff G.A., Ross J.A., and Perentesis J.P. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J. Clin. Oncol. 19 (2001) 1279-1287
15. Dirven H.A., van Ommen B., and van Bladeren P.J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 54 (1994) 6215-6220
16. Dirven H.A., van Ommen B., and van Bladeren P.J. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem. Res. Toxicol. 9 (1996) 351-360
17. Fucic A., Jazbec A., Mijic A., Seso-Simic D., and Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat. Res. 416 (1998) 59-66
18. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmoller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields P.G., Sim E., Sinnet D., Strange R.C., Stucker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., and Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol., Biomarkers Prev. 10 (2001) 1239-1248
19. Gazzetta Ufficiale, 236. Ministero della Sanità, Dipartimento della Prevenzione. Commissione Oncologica Nazionale. Linee Guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario (1999)
20. Goloni-Bertollo E.M., Tajara E.H., Manzato A.J., and Varella-Garcia M. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int. J. Cancer 50 (1992) 341-344
21. Hagmar L., Brogger A., Hansteen I.L., Heim S., Hogstedt B., Knudsen L., Lambert B., Linnainmaa K., Mitelman F., and Nordenson I. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res. 54 (1994) 2919-2922
22. Hagmar L., Bonassi S., Stromberg U., Brogger A., Knudsen L.E., Norppa H., and Reuterwall C. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 58 (1998) 4117-4121
23. Hagmar L., Stromberg U., Tinnerberg H., and Mikoczy Z. Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer. IARC Sci. Publ. 157 (2004) 207-215
24. Hall A.G., Autzen P., Cattan A.R., Malcolm A.J., Cole M., Kernahan J., and Reid M.M. Expression of mu class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res. 54 (1994) 5251-5254
25. Harries L.W., Stubbins M.J., Forman D., Howard G.C., and Wolf C.R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18 (1997) 641-644
26. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30 (1995) 445-600
27. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., and Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14 (1993) 1479-1481
28. International Agency for Research on Cancer. International Agency for Research on Cancer Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. Eval. Carcinog. Risks. Hum. Suppl. 7 (1987) 1-440
29. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Pharmaceutical Drugs, IARC. Monogr. Eval. Carcinog. Risks Hum. 50 (1990) 47-123
30. Jacobson-Kram D., Albertini R.J., Branda R.F., Falta M.T., Iype P.T., Kolodner K., Liou S.H., McDiarmid M.A., Morris M., and Nicklas J.A. Measurement of chromosomal aberrations, sister chromatid exchange, hprt mutations, and DNA adducts in peripheral lymphocytes of human populations at increased risk for cancer. Environ. Health Perspect. 101 Suppl. 3 (1993) 121-125
31. Jakab M.G., Major J., and Tompa A. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J. Toxicol. Environ. Health, A 62 (2001) 307-318
32. Kelsey K.T., Hankinson S.E., Colditz G.A., Springer K., Garcia-Closas M., Spiegelman D., Manson J.E., Garland M., Stampfer M.J., Willett W.C., Speizer F.E., and Hunter D.J. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol., Biomarkers Prev. 6 (1997) 511-515
33. Krepinsky A., Bryant D.W., Davison L., Young B., Heddle J., McCalla D.R., Douglas G., and Michalko K. Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ. Mol. Mutagen. 15 (1990) 83-92
34. Liou S.H., Lung J.C., Chen Y.H., Yang T., Hsieh L.L., Chen C.J., and Wu T.N. Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res. 59 (1999) 1481-1484
35. Machado-Santelli G.M., Cerqueira E.M., Oliveira C.T., and Pereira C.A. Biomonitoring of nurses handling antineoplastic drugs. Mutat. Res. 322 (1994) 203-208
36. Milkovic-Kraus S., and Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am. J. Ind. Med. 19 (1991) 771-774
37. Nikula E., Kiviniitty K., Leisti J., and Taskinen P.J. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand. J. Work Environ. Health 10 (1984) 71-74
38. Norppa H. Genetic polymorphisms and chromosome damage. Int. J. Hyg. Environ. Health 204 (2001) 31-38
39. Norppa H., Sorsa M., Vainio H., Grohn P., Heinonen E., Holsti L., and Nordman E. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand. J. Work, Environ. & Health 6 (1980) 299-301
40. Norppa H., Bonassi S., Hansteen I.L., Hagmar L., Stromberg U., Rossner P., Boffetta P., Lindholm C., Gundy S., Lazutka J., Cebulska-Wasilewska A., Fabianova E., Sram R.J., Knudsen L.E., Barale R., and Fucic A. Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutat. Res. 600 (2006) 37-45
41. Oestreicher U., Stephan G., and Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat. Res. 242 (1990) 271-277
42. Pilger A., Kohler I., Stettner H., Mader R.M., Rizovski B., Terkola R., Diem E., Franz-Hainzl E., Konnaris C., Valic E., and Rudiger H.W. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs. Int. Arch. Occup. Environ. Health 73 (2000) 442-448
43. Pohlova H., Cerna M., and Rossner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat. Res. 174 (1986) 213-217
44. Povirk L.F., and Austin M.J. Genotoxicity of bleomycin. Mutat. Res. 257 (1991) 127-143
45. Rossner P., Boffetta P., Ceppi M., Bonassi S., Smerhovsky Z., Landa K., Juzova D., and Sram R.J. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environ. Health Perspect. 113 (2005) 517-520
46. Rowe J.D., Nieves E., and Listowsky I. Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochem. J. 325 Pt. 2 (1997) 481-486
47. Rubes J., Kucharova S., Vozdova M., Musilova P., and Zudova Z. Cytogenetic analysis of peripheral lymphocytes in medical personnel by means of FISH. Mutat. Res. 412 (1998) 293-298
48. Sessink P.J., Cerna M., Rossner P., Pastorkova A., Bavarova H., Frankova K., Anzion R.B., and Bos R.P. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat. Res. 309 (1994) 193-199
49. Smerhovsky Z., Landa K., Rossner P., Brabec M., Zudova Z., Hola N., Pokorna Z., Mareckova J., and Hurychova D. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ. Health Perspect. 109 (2001) 41-45
50. Smerhovsky Z., Landa K., Rossner P., Juzova D., Brabec M., Zudova Z., Hola N., Zarska H., and Nevsimalova E. Increased risk of cancer in radon-exposed miners with elevated frequency of chromosomal aberrations. Mutat. Res. 514 (2002) 165-176
51. Stanulla M., Schrappe M., Brechlin A.M., Zimmermann M., and Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95 (2000) 1222-1228
52. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., and Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 94 (2002) 936-942
53. Sweeney C., McClure G.Y., Fares M.Y., Stone A., Coles B.F., Thompson P.A., Korourian S., Hutchins L.F., Kadlubar F.F., and Ambrosone C.B. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 60 (2000) 5621-5624
54. Turci R., Sottani C., Spagnoli G., and Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J. Chromatogr., B Analyt Technol. Biomed. Life. Sci. 789 (2003) 69-209
55. van Ommen B., Bogaards J.J., Peters W.H., Blaauboer B., and van Bladeren P.J. Quantification of human hepatic glutathione S-transferases. Biochem. J. 269 (1990) 609-613
56. Vineis P. Individual susceptibility to carcinogens. Oncogene 23 (2004) 6477-6483
57. Waksvik H., Klepp O., and Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat. Rep. 65 (1981) 607-610
58. Zhon g S., Wyllie A.H., Barnes D., Wolf C.R., and Spurr N.K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14 (1993) 1821-1824